– Independent Radiology Review Committee
confirms primary endpoint analysis per investigator: cabozantinib
provided statistically significant improvement of progression-free
survival, with a 52 percent reduction in the rate of progression or
death compared to sunitinib –
– Exelixis and Ipsen to host investor and media
webcast from Madrid to discuss the data on Sunday, September 10
starting at 6:45 p.m. CEST –
Exelixis, Inc. (NASDAQ:EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY)
today announced updated results from the CABOSUN randomized phase 2
trial of cabozantinib in patients with previously untreated
advanced renal cell carcinoma (RCC) with intermediate- or poor-risk
disease per the International Metastatic Renal Cell Carcinoma
Database Consortium (IMDC). Principal investigator Toni K.
Choueiri, M.D., will present detailed data from late-breaking
CABOSUN abstract [#LBA38_PD] today in the Genitourinary Tumors,
Non-Prostate poster discussion session, starting at 2:45 p.m. CEST
(local Madrid time) / 8:45 a.m. EDT / 5:45 a.m. PDT at the European
Society for Medical Oncology (ESMO) 2017 Congress, which is being
held September 8-12, 2017 in Madrid, Spain.
CABOSUN is being conducted by The Alliance for Clinical Trials
in Oncology as part of Exelixis’ collaboration with the National
Cancer Institute’s Cancer Therapy Evaluation Program (NCI-CTEP).
The data presented at ESMO 2017 included the analysis from a
blinded independent radiology review committee (IRC), which
confirmed the primary efficacy endpoint results of
investigator-assessed progression-free survival (PFS), as well as
an updated investigator-assessed analysis. Per the IRC analysis,
cabozantinib demonstrated a clinically meaningful and statistically
significant 52 percent reduction in the rate of disease progression
or death (HR 0.48, 95% CI 0.31-0.74, two-sided P=0.0008). The
median PFS for cabozantinib was 8.6 months versus 5.3 months for
sunitinib, corresponding to a 3.3 month (62 percent) improvement
favoring cabozantinib over sunitinib.
“These updated analyses from CABOSUN consistently show that
cabozantinib provided a statistically significant decrease in the
rate of disease progression or death compared to sunitinib, a
current standard of care – potentially offering a new treatment
option for physicians to treat patients in the first-line advanced
renal cell carcinoma setting,” said Toni K. Choueiri, M.D.,
Director, Lank Center for Genitourinary Oncology, Dana-Farber
Cancer Institute. “The CABOSUN trial included patients with
intermediate or poor prognostic factors per the IMDC criteria; in
addition, patients had a notable number of other independent
adverse prognostic risk factors. These included a high rate of bone
metastases, two or more sites of metastatic disease, ECOG 2
performance status, and lack of prior nephrectomy. This patient
population fares poorly and is in need of new therapies to better
control their disease.”
The following chart outlines data from the CABOSUN trial
presented today at ESMO 2017, as compared to the data previously
published in the Journal of Clinical Oncology (JCO) in October
2016:
JCO
Investigator-assessed(April 11,
2016 Cut-off)
ESMO 2017 Investigator-assessed
(Sept 15, 2016 Cut-off)
ESMO 2017
IRC Review
(Sept 15, 2016 Cut-off)
CabozantinibN = 79
SunitinibN = 78
CabozantinibN = 79
SunitinibN = 78
CabozantinibN = 79
SunitinibN = 78 Progression-free survival
Median PFS, months 8.2 5.6
8.3 5.4 8.6
5.3
Stratified HR (95% CI) 0.66
(0.46-0.95) 0.56 (0.37-0.83)
0.48 (0.31-0.74)
P value 0.012 (1-sided)
0.0042 (2-sided) 0.0008
(2-sided)
Tumor Response Objective response rate (95%
CI),a % 46 (34-57) 18
(10-28) 33 (23-44) 12
(5-21) 20 (12-31) 9
(4-18)
Disease control rate,b % 78
54 76 49
75 47
Progressive
disease,c % 18 26
18 24 18
29
Not evaluable or missing, % 4
21 6 27
8 23
Any reduction in
target lesions, % 87 44
85 38 80
50 a One complete response was observed with
cabozantinib for both investigator assessments, and one complete
response was observed with sunitinib for the original investigator
assessment, all other responses were partial responses; b Complete
response + partial response + stable disease; c Progressive disease
as best overall response.
The updated 2017 data sets and methods differ from the initial
investigator analyses presented in 2016. The comprehensive image
collection for IRC review used a later cut-off point (5 months)
than the initial investigator analysis and followed a rigorous IRC
review process. The analysis of IRC data applied U.S. Food and Drug
Administration (FDA) guidance for PFS analyses in oncology studies,
including recommended censoring rules (i.e., censoring at the last
adequate tumor assessment prior to initiation of subsequent
anti-cancer therapy, and censoring for events that occur after two
or more missing adequate tumor assessments).1 Both the updated
investigator assessment and IRC analysis demonstrated consistent
and statistically significant improvement of PFS with cabozantinib
as compared to sunitinib.
The updated overall survival (OS) analysis had a data cut-off of
July 1, 2017, and showed a favorable trend for patients randomized
to cabozantinib compared to sunitinib that was not statistically
significant. Median overall survival was 26.6 months for patients
receiving cabozantinib versus 21.2 months for those receiving
sunitinib (HR= 0.80, 95% CI 0.53-1.21, two-sided P=0.29).
“We are very encouraged by the clinically meaningful and
statistically significant efficacy results on the primary endpoint
of progression-free survival, which formed the basis of the recent
supplemental New Drug Application submitted to the U.S. Food and
Drug Administration for cabozantinib in first-line advanced renal
cell carcinoma,” said Michael M. Morrissey, Ph.D., President and
Chief Executive Officer of Exelixis. “The latest CABOSUN data
continue to underscore the value that cabozantinib may offer
patients with previously untreated renal cell carcinoma, and we are
working tirelessly in our efforts to bring this option to patients
and their physicians as quickly as possible.”
David Meek, Chief Executive Officer of Ipsen stated, “Following
the recent European approval of cabozantinib for second-line
treatment of patients with advanced renal cell carcinoma following
prior VEGF-targeted therapy, the latest data from the CABOSUN study
being presented this year at ESMO extends the clinical benefit of
cabozantinib in first-line therapy setting for patients with
advanced RCC. With our partner Exelixis, we are committed to
strengthening the medical value of cabozantinib and to continuing
to bring innovative therapeutic solutions for the treatment of
patients with RCC."
The most common all-causality grade 3 or 4 adverse events in
more than 5 percent of patients for cabozantinib (N=78) and
sunitinib (N=72), respectively, were diarrhea (10 vs. 11 percent),
hypertension (28 vs. 21 percent), fatigue (6 vs. 17 percent),
increased alanine aminotransferase (ALT; 5 vs. 0 percent),
decreased appetite (5 vs. 1 percent), palmar-plantar
erythrodysesthesia syndrome (PPES; 8 vs. 4 percent), decreased
platelet count (1 vs. 11 percent) and stomatitis (5 vs. 6 percent).
Twenty-one percent of patients in the cabozantinib arm and 22
percent of patients in the sunitinib arm discontinued treatment due
to adverse events.
Exelixis filed a supplemental New Drug Application based on the
CABOSUN data with the FDA for cabozantinib as a treatment for
previously untreated advanced RCC on August 16, 2017. Ipsen also
submitted to EMA the regulatory dossier for cabozantinib as a
treatment for first-line advanced RCC in the European Union on
August 28, 2017; on September 8, 2017, Ipsen announced that the EMA
validated the application.
About the CABOSUN Study
On May 23, 2016, Exelixis announced that CABOSUN met its primary
endpoint, demonstrating a statistically significant and clinically
meaningful improvement in PFS compared with sunitinib in patients
with advanced intermediate- or poor-risk RCC as determined by
investigator assessment. The CABOSUN trial is being conducted by
The Alliance for Clinical Trials in Oncology as part of Exelixis’
collaboration with the NCI-CTEP. These results were first presented
in a plenary session by Dr. Toni Choueiri at the ESMO 2016
Congress, and published in the JCO.2 In June 2017, a blinded IRC
confirmed that cabozantinib provided a clinically meaningful and
statistically significant improvement in the primary efficacy
endpoint of investigator-assessed PFS.
CABOSUN is a randomized, open-label, active-controlled phase 2
trial that enrolled 157 patients with advanced RCC determined to be
intermediate- or poor-risk by the IMDC criteria. Patients were
randomized 1:1 to receive cabozantinib (60 mg once daily) or
sunitinib (50 mg once daily, 4 weeks on followed by 2 weeks off).
The primary endpoint was PFS. Secondary endpoints included OS and
objective response rate.
Eligible patients were required to have locally advanced or
metastatic clear-cell RCC, ECOG performance status 0-2 and had to
be intermediate or poor risk per the IMDC criteria (Heng, JCO,
2009).3 Prior systemic treatment for RCC was not permitted.
Baseline characteristics included:
Characteristic Cabozantinib (N=79)
Sunitinib (N=78) ECOG performance status, %
0 46 46 1 42 41 2 13 13
IMDC
risk group, % Intermediate 81 81
Poor 19 19
Bone metastasis per IxRS,a %
Yes 37 36 No 63 64
Prior nephrectomy, %
Yes 72 77 No 28 23
Number of
metastatic sites per investigator, % 1 22
33 2 47 26 ≥3 32 41 a interactive voice/web response
system
Please see Important Safety Information below and full U.S.
prescribing information at
https://cabometyx.com/downloads/cabometyxuspi.pdf.
Webcast for the Financial Community and Media
Exelixis and its partner Ipsen will jointly host a live webcast
on Sunday, September 10. The webcast will begin at 6:45 p.m. CEST
(local Madrid time) / 12:45 p.m. EDT / 9:45 a.m. PDT. During the
webcast, Exelixis and Ipsen management and invited guest speakers
will review results from the CABOSUN trial, along with the other
relevant data sets presented at the conference.
To access the webcast link, log onto www.exelixis.com and
proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s
website at least 15 minutes prior to the webcast to ensure adequate
time for any software download that may be required to view the
program. To listen to an audio-only version of the program by
phone, please dial (855) 793-2457 (domestic) or (631) 485-4921
(international/toll dial) and use passcode 68961937. A telephone
replay will be available until 11:59 p.m. EDT on September 17,
2017. Access numbers for the telephone replay are: 855-859-2056
(domestic) and 404-537-3406 (international); the passcode is
68961937. A webcast replay will also be available archived on
www.exelixis.com for one year.
About Advanced Renal Cell Carcinoma
The American Cancer Society’s 2017 statistics cite kidney cancer
as among the top ten most commonly diagnosed forms of cancer among
both men and women in the U.S.4 Clear cell RCC is the most common
type of kidney cancer in adults.5 If detected in its early stages,
the five-year survival rate for RCC is high; for patients with
advanced or late-stage metastatic RCC, however, the five-year
survival rate is only 12 percent, with no identified cure for the
disease.6 Approximately 30,000 patients in the U.S. and 68,000
globally require treatment, and an estimated 14,000 patients in the
U.S. each year are in need of a first-line treatment for advanced
kidney cancer.7
The majority of clear cell RCC tumors have lower than normal
levels of a protein called von Hippel-Lindau, which leads to higher
levels of MET, AXL and VEGF.8,9 These proteins promote tumor
angiogenesis (blood vessel growth), growth, invasiveness and
metastasis.10-13 MET and AXL may provide escape pathways that drive
resistance to VEGF receptor inhibitors.8,9
About CABOMETYX® (cabozantinib)
CABOMETYX is the tablet formulation of cabozantinib. Its targets
include MET, AXL and VEGFR-1, -2 and -3. In preclinical models,
cabozantinib has been shown to inhibit the activity of these
receptors, which are involved in normal cellular function and
pathologic processes such as tumor angiogenesis, invasiveness,
metastasis and drug resistance. CABOMETYX is available in 20 mg, 40
mg or 60 mg doses. The recommended dose is 60 mg orally, once
daily.
On April 25, 2016, the FDA approved CABOMETYX tablets for the
treatment of patients with advanced RCC who have received prior
anti-angiogenic therapy. In February of 2016, Exelixis and Ipsen
jointly announced an exclusive licensing agreement for the
commercialization and further development of cabozantinib
indications outside of the United States, Canada and Japan. This
agreement was amended in December of 2016 to include
commercialization rights for Ipsen in Canada. On September 9, 2016,
the European Commission approved CABOMETYX tablets for the
treatment of advanced RCC in adults who have received prior
vascular endothelial growth factor (VEGF)-targeted therapy in the
European Union, Norway and Iceland.
On January 30, 2017, Exelixis and Takeda Pharmaceutical Company
Limited announced an exclusive licensing agreement for the
commercialization and further clinical development of cabozantinib
for all future indications in Japan, including RCC.
CABOMETYX is not indicated for the treatment of previously
untreated advanced RCC.
U.S. Important Safety Information
Hemorrhage: Severe hemorrhage occurred with CABOMETYX.
The incidence of Grade ≥3 hemorrhagic events was 2.1% in
CABOMETYX-treated patients and 1.6% in everolimus-treated patients.
Fatal hemorrhages also occurred in the cabozantinib clinical
program. Do not administer CABOMETYX to patients that have or are
at risk for severe hemorrhage.
Gastrointestinal (GI) Perforations and Fistulas: Fistulas
were reported in 1.2% (including 0.6% anal fistula) of
CABOMETYX-treated patients and 0% of everolimus-treated patients.
GI perforations were reported in 0.9% of CABOMETYX-treated patients
and 0.6% of everolimus-treated patients. Fatal perforations
occurred in the cabozantinib clinical program. Monitor patients for
symptoms of fistulas and perforations. Discontinue CABOMETYX in
patients who experience a fistula that cannot be appropriately
managed or a GI perforation.
Thrombotic Events: CABOMETYX treatment results in an
increased incidence of thrombotic events. Venous thromboembolism
was reported in 7.3% of CABOMETYX-treated patients and 2.5% of
everolimus-treated patients. Pulmonary embolism occurred in 3.9% of
CABOMETYX-treated patients and 0.3% of everolimus-treated patients.
Events of arterial thromboembolism were reported in 0.9% of
CABOMETYX-treated patients and 0.3% of everolimus-treated patients.
Fatal thrombotic events occurred in the cabozantinib clinical
program. Discontinue CABOMETYX in patients who develop an acute
myocardial infarction or any other arterial thromboembolic
complication.
Hypertension and Hypertensive Crisis: CABOMETYX treatment
results in an increased incidence of treatment-emergent
hypertension. Hypertension was reported in 37% (15% Grade ≥3) of
CABOMETYX-treated patients and 7.1% (3.1% Grade ≥3) of
everolimus-treated patients. Monitor blood pressure prior to
initiation and regularly during CABOMETYX treatment. Withhold
CABOMETYX for hypertension that is not adequately controlled with
medical management; when controlled, resume CABOMETYX at a reduced
dose. Discontinue CABOMETYX for severe hypertension that cannot be
controlled with anti-hypertensive therapy. Discontinue CABOMETYX if
there is evidence of hypertensive crisis or severe hypertension
despite optimal medical management.
Diarrhea: Diarrhea occurred in 74% of patients treated
with CABOMETYX and in 28% of patients treated with everolimus.
Grade 3 diarrhea occurred in 11% of CABOMETYX-treated patients and
in 2% of everolimus-treated patients. Withhold CABOMETYX in
patients who develop intolerable Grade 2 diarrhea or Grade 3-4
diarrhea that cannot be managed with standard antidiarrheal
treatments until improvement to Grade 1; resume CABOMETYX at a
reduced dose. Dose modification due to diarrhea occurred in 26% of
patients.
Palmar-Plantar Erythrodysesthesia Syndrome (PPES):
Palmar-plantar erythrodysesthesia syndrome (PPES) occurred in 42%
of patients treated with CABOMETYX and in 6% of patients treated
with everolimus. Grade 3 PPES occurred in 8.2% of CABOMETYX-treated
patients and in <1% of everolimus-treated patients. Withhold
CABOMETYX in patients who develop intolerable Grade 2 PPES or Grade
3 PPES until improvement to Grade 1; resume CABOMETYX at a reduced
dose. Dose modification due to PPES occurred in 16% of
patients.
Reversible Posterior Leukoencephalopathy Syndrome (RPLS):
RPLS, a syndrome of subcortical vasogenic edema diagnosed by
characteristic finding on MRI, occurred in the cabozantinib
clinical program. Perform an evaluation for RPLS in any patient
presenting with seizures, headache, visual disturbances, confusion,
or altered mental function. Discontinue CABOMETYX in patients who
develop RPLS.
Embryo-fetal Toxicity: CABOMETYX can cause fetal harm
when administered to a pregnant woman. Advise pregnant women of the
potential risk to a fetus. Advise females of reproductive potential
to use effective contraception during treatment with CABOMETYX and
for 4 months after the last dose.
Adverse Reactions: The most commonly reported (≥25%)
adverse reactions are: diarrhea, fatigue, nausea, decreased
appetite, PPES, hypertension, vomiting, weight decreased, and
constipation.
Drug Interactions: Strong CYP3A4 inhibitors and inducers:
Reduce the dosage of CABOMETYX if concomitant use with strong
CYP3A4 inhibitors cannot be avoided. Increase the dosage of
CABOMETYX if concomitant use with strong CYP3A4 inducers cannot be
avoided.
Lactation: Advise a lactating woman not to breastfeed
during treatment with CABOMETYX and for 4 months after the final
dose.
Reproductive Potential: Contraception―Advise females of
reproductive potential to use effective contraception during
treatment with CABOMETYX and for 4 months after the final dose.
Infertility ―CABOMETYX may impair fertility in females and
males of reproductive potential.
Hepatic Impairment: Reduce the CABOMETYX dose in patients
with mild (Child-Pugh score [C-P] A) or moderate (C-P B) hepatic
impairment. CABOMETYX is not recommended for use in patients with
severe hepatic impairment.
Please see full Prescribing Information at
https://cabometyx.com/downloads/cabometyxuspi.pdf.
About Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in
model genetic systems, we established a broad drug discovery and
development platform that has served as the foundation for our
continued efforts to bring new cancer therapies to patients in
need. We discovered our lead compounds, cabozantinib and
cobimetinib, and advanced them into clinical development before
entering into partnerships with leading biopharmaceutical companies
in our efforts to bring them to patients globally. With growing
revenues from the three resulting commercialized products –
CABOMETYX®, COMETRIQ®, and COTELLIC® – we are reinvesting in our
business to maximize the potential of our pipeline, which we intend
to supplement with targeted business development activities and
internal drug discovery, all to deliver the next generation of
Exelixis medicines and help patients recover stronger and live
longer. For more information about Exelixis, please visit
www.exelixis.com or follow @ExelixisInc on Twitter.
About Ipsen
Ipsen is a global specialty-driven pharmaceutical group with
total sales exceeding €1.4 billion in 2015. Ipsen sells more than
20 drugs in more than 115 countries, with a direct commercial
presence in more than 30 countries. Ipsen’s ambition is to become a
leader in specialty healthcare solutions for targeted debilitating
diseases. Its fields of expertise cover oncology, neurosciences and
endocrinology (adult & pediatric). Ipsen’s commitment to
oncology is exemplified through its growing portfolio of key
therapies improving the care of patients suffering from prostate
cancer, bladder cancer and neuro-endocrine tumors. Ipsen also has a
significant presence in primary care. Moreover, the Group has an
active policy of partnerships. Ipsen's R&D is focused on its
innovative and differentiated technological platforms, peptides and
toxins, located in the heart of the leading biotechnological and
life sciences hubs (Les Ulis/Paris-Saclay, France; Slough/Oxford,
UK; Cambridge, US). In 2015, R&D expenditure totaled close to
€193 million. The Group has more than 4,600 employees worldwide.
Ipsen’s shares are traded on segment A of Euronext Paris (stock
code: IPN, ISIN code: FR0010259150) and eligible to the “Service de
Règlement Différé” (“SRD”). The Group is part of the SBF 120 index.
Ipsen has implemented a Sponsored Level I American Depositary
Receipt (ADR) program, which trade on the over-the-counter market
in the United States under the symbol IPSEY. For more information
on Ipsen, visit www.ipsen.com.
Exelixis Forward-Looking Statement Disclaimer
This press release contains forward-looking statements,
including, without limitation, statements related to: the
presentation of detailed data from CABOSUN at ESMO; the therapeutic
potential of cabozantinib as a treatment for patients with
previously untreated RCC; the commitment of Exelixis its partner
Ipsen to strengthening the medical value of cabozantinib and to
continuing to bring innovative therapeutic solutions for the
treatment of patients with RCC; and the continued development of
cobimetinib and its potential in a variety of forms of cancer.
Words such as “will,” “potentially,” “may,” “committed,”
“continue,” or other similar expressions identify forward-looking
statements, but the absence of these words does not necessarily
mean that a statement is not forward-looking. In addition, any
statements that refer to expectations, projections or other
characterizations of future events or circumstances are
forward-looking statements. These forward-looking statements are
based upon Exelixis’ current plans, assumptions, beliefs,
expectations, estimates and projections. Forward-looking statements
involve risks and uncertainties. Actual results and the timing of
events could differ materially from those anticipated in the
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation: the availability
of data at the referenced times; risks related to the potential
failure of cabozantinib to demonstrate safety and efficacy in
clinical testing; risks and uncertainties related to regulatory
review and approval processes and Exelixis’ compliance with
applicable legal and regulatory requirements; Exelixis’ dependence
on its relationship with Genentech/Roche with respect to
cobimetinib and Exelixis’ ability to maintain its rights under the
collaboration; Exelixis’ ability to protect the company’s
intellectual property rights; market competition; changes in
economic and business conditions, and other factors discussed under
the caption “Risk Factors” in Exelixis’ quarterly report on Form
10-Q filed with the Securities and Exchange Commission (SEC)
on August 2, 2017, and in Exelixis’ future filings with the SEC.
The forward-looking statements made in this press release speak
only as of the date of this press release. Exelixis expressly
disclaims any duty, obligation or undertaking to release publicly
any updates or revisions to any forward-looking statements
contained herein to reflect any change in Exelixis’ expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statements are based.
Exelixis, the Exelixis logo, CABOMETYX,
COMETRIQ and COTELLIC are registered U.S. trademarks.
References
1. Guidance for Industry: Clinical Trial Endpoints for the
Approval of Cancer Drugs and Biologics. U.S. Department of Health
and Human Services Food and Drug Administration; May 2007.
2. Choueiri, T.K., et al. Cabozantinib versus Sunitinib as
Initial Targeted Therapy for Patients with Metastatic Renal Cell
Carcinoma of Poor or Intermediate Risk: The Alliance A031203
CABOSUN Trial. Am J Clin Oncol. 2016; 35:591-597.
3. Heng D.Y., Xie W., Regan M.M., et al. Prognostic factors for
overall survival in patients with metastatic renal cell carcinoma
treated with vascular endothelial growth factor-targeted agents:
Results from a large, multicenter study. Am J Clin Oncol. 2009;
27:5794-5799.
4. American Cancer Society. Cancer Facts & Figures 2017.
Atlanta: American Cancer Society; 2017.
5. Jonasch, E., Gao, J., Rathmell, W. Renal cell carcinoma. BMJ.
2014; 349:g4797.
6. Ko, J., Choueiri, T., et al. First-, second- third-line
therapy for mRCC: benchmarks for trial design from the IMDC. Br J
Cancer. 2014; 110:1917-1922.
7. Decision Resources Report: Renal Cell Carcinoma. October 2014
(internal data on file).
8. Harshman, L., and Choueiri, T. Targeting the hepatocyte
growth factor/c-Met signaling pathway in renal cell carcinoma.
Cancer J. 2013; 19:316-323.
9. Rankin, et al. Direct regulation of GAS6/AXL signaling by HIF
promotes renal metastasis through SRC and MET. Proc Natl Acad Sci U
S A. 2014; 111:13373-13378.
10. Zhou, L., Liu, X-D., Sun, M., et al. Targeting MET and AXL
overcomes resistance to sunitinib therapy in renal cell carcinoma.
Oncogene. 2016; 35:2687-2697.
11. Koochekpour, et al. The von Hippel-Lindau tumor suppressor
gene inhibits hepatocyte growth factor/scatter factor-induced
invasion and branching morphogenesis in renal carcinoma cells. Mol
Cell Biol. 1999; 19:5902–5912.
12. Takahashi, A., Sasaki, H., Kim, S., et al. Markedly
increased amounts of messenger RNAs for vascular endothelial growth
factor and placenta growth factor in renal cell carcinoma
associated with angiogenesis. Cancer Res. 1994; 54:4233-4237.
13. Nakagawa, M., Emoto, A., Hanada, T., Nasu, N., Nomura, Y.
Tubulogenesis by microvascular endothelial cells is mediated by
vascular endothelial growth factor (VEGF) in renal cell carcinoma.
Br J Urol. 1997; 79:681-687.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170909005044/en/
Exelixis, Inc.InvestorsSusan Hubbard, 650-837-8194EVP,
Public Affairs and Investor
Relationsshubbard@exelixis.comorMediaLindsay Treadway,
650-837-7522Director, Public Affairs and Advocacy
Relationsltreadway@exelixis.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Apr 2023 to Apr 2024